How this little UK stock is working to revolutionise vaccines

Vaccines have transformed human and animal health, helping to prevent millions of deaths and bringing once-feared diseases under control. In some cases, such as smallpox, vaccination has even helped eradicate a disease worldwide.

But what if vaccines could be made to work even better?

That's the possibility one small-cap UK stock, Aptamer Group (AIM: APTA) , is exploring through its work on synthetic molecules designed to enhance immune responses.

If successful, the company's technology could give vaccine developers another tool to improve vaccine performance, while opening up a potential royalty stream for Aptamer from vaccines that incorporate its technology.

How vaccines work

Vaccines are a core part of preventative medicine.

They train the immune system to recognise and respond to a threat before it causes serious illness.

Basically, vaccines expose the immune system to a substance that mimics a virus or pathogen. The body recognises this as a foreign substance and gives instructions to fight it. The result is that if the person encounters virus or pathogen in the future, the body is already prepared as to how to combat it, potentially preventing the illness or reducing its severity.

But developing an effective vaccine isn't always straightforward. 

Different pathogens present different challenges, and vaccines need to be designed to trigger the right immune response.

Influenza is a good example. Flu viruses evolve rapidly, and different strains circulate over time, making it difficult to ensure a vaccine remains well matched to the viruses people encounter. Measles, by comparison, is genetically more stable, helping make it possible to develop a highly effective vaccine that has dramatically reduced infections wherever vaccination coverage is high.

There are other challenges, too. Some vaccines need additional ingredients to help stimulate an effective immune response, while certain treatments and vaccine technologies face difficulties getting their active ingredients to the right cells or tissues.

These challenges have created opportunities to explore new approaches to vaccine design.

Building a vaccine, but with teeth

Creating a vaccine is one thing. Making sure it triggers the right immune response is another.

Some vaccines benefit from an additional ingredient called an adjuvant, which helps stimulate or shape the immune response. Depending on the vaccine, this can produce a stronger or more durable response, potentially improving protection against disease.

Think of a vaccine as an army preparing to defend against an invading virus. An adjuvant acts like a reinforcement, helping rally the troops and strengthen their response when the enemy arrives.

Aptamer Group is exploring whether its proprietary synthetic molecules, known as Optimers, could play that supporting role.

Optimers are designed to recognise and bind to specific biological targets. Their potential application as vaccine adjuvants offers researchers another way to influence how the immune system responds.

The company’s technology also relies on synthetic production, which may offer practical advantages in areas such as consistency, stability and scalability, depending on the application. However, these potential manufacturing benefits are distinct from the bigger question: can Optimers help vaccines generate a more effective protective response?

That is the promise researchers are investigating. While encouraging early findings may support further development, additional testing is needed to establish whether Optimers can improve protection against disease in practice.

Can Aptamer Group turn its technology into a business?

The big question is whether Aptamer Group can turn its scientific research into a sustainable business.

The company aims to commercialise its Optimer platform through research projects, licensing agreements and royalties from products incorporating its technology. Its vaccine work with the University of Glasgow, which began in 2025, offers one example, with Aptamer potentially earning royalties (as high as 10% of all downstream sales) from future vaccines that use its Optimers as adjuvants.

Vaccines are just one potential application, with further opportunities in areas such as diagnostics and drug development.

Of course, scientific promise doesn't guarantee commercial success. Research can take years to reach market, further testing may disappoint, and licensing agreements don't guarantee products will generate meaningful revenue. As is the case with emerging biotechs which are being trialled, it also requires the company to maintain enough cash to survive until its products are approved for use if that ever happens at all.

Aptamer's technology could eventually serve multiple industries, but the challenge is turning that potential into paying customers, commercial products and recurring revenue.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Simply Wall St analyst Andrew Legget and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.